Sign inJoin waitlistJoin the waitlist

Seth M. Pollack

Professor, Feinberg School of Medicine · Feinberg School of Medicine

Credentials: · · · · ·

History

Feinberg School of Medicine
Present

University of Washington
Until 2011
George Washington University
Until 2008
George Washington University School of Medicine and Health Sciences
2005

Research

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 336 citations
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial
The Lancet · 2024 · 258 citations
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas
Cancer · 2017 · First of 24 authors · 226 citations

RJ
Robin Jones
49 papers
Elizabeth Loggers
28 papers
LC
Lee Cranmer
21 papers
Michael Wagner
20 papers
Borislav Alexiev
15 papers
BS
Brett Schroeder
13 papers · 10 as a resident
Venu Pillarisetty
11 papers
Pedro de Viveiros
10 papers · 2 as a fellow
BT
Brian Van Tine
9 papers
Cassian Yee
9 papers
Eve Rodler
9 papers
Mark Agulnik
8 papers

Grants

Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model
National Cancer Institute · R01
Contact PI · $1.3M · Northwestern University
2025–2030
Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMV
National Cancer Institute · R01
Contact PI · $1.3M · Northwestern University
2025–2029
LiT4Q TLR4 Agonist Formulation for Mucosal Melanoma
National Cancer Institute · R43
PI · $391.3K · Pai Life Sciences, Inc.
2026–2027
Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors
National Cancer Institute · R01
Contact PI · $2.5M · Northwestern University
2019–2025

Clinical trials

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
Principal investigator · Recruiting · Early phase 1
Seth Pollack
2026–2032
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Principal investigator · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Principal investigator · Withdrawn · Phase 2
Fred Hutchinson Cancer Center
2018–2021
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Principal investigator · Terminated · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2017–2020